Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HLTT(.45)...complex/interesting situation developing here.....
There are a lot of very complex elements going on with HLTT right now (they have a need for financing, revenue from their Amniobind product is expected to begin, other risks/catalysts you might expect from a biotech/medical company, etc). I have no idea how everything is going to play out (could be extremely good or extremely bad), but it is certainly an interesting situation.
One aspect of HLTT that is particularly interesting at the moment is its 5.5% ownership position in privately-held Varian Biopharma. Originally Varian was planning to go public via HLTT, but I think Varian/HLTT had difficulty attracting financing. Both parties mutually agreed to abandon the plan. So Varian then entered into a potential acquisition deal with SPK (a Nasdaq SPAC). As with most SPAC deals it is taking a considerable amount of time to get the deal closed.
Recently SPK mentioned in its filings that as part of closing the deal a simultaneous private placement was being worked on. I found that a bit interesting (and somewhat unusual) because the SPAC already had a fairly decent amount of cash (around $50M). SPK recently had its vote to extend the time for the SPAC to complete its acquisition and the 8-K disclosed a couple of items that caught my attention: 1) One day before the vote an institutional investor agreed to pay the first month's extension. I am not entirely sure but it is possible this investor may not have had any previous relationship with this SPAC. 2) More than 61% of the SPAC's shares were tendered for redemption. There are now only a little more than 2.5M shares outstanding in this SPAC.
That recent disclosure of work being done on a private placement and the institutional investor paying the first extension almost suggests to me that SPK probably was aware there would be a high number of redemptions but SPK/Varian might still be interested in trying to get a deal completed. If that is the case it will be interesting to see what kind of adjustments might be made to the original terms of the deal and what (if any) positive/negative impact it might have on HLTT. Under the original deal, HLTT was going to own a little more than 2.2% of the post-merger company.
Perhaps worth noting: Ever since HLTT issued 25-cent stock options to a debt holder on September 6 (the stock was trading around 20 cents at the time), and SPK had its extension vote on September 9, HLTT has quietly doubled in price. HLTT's ownership position in Varian Biopharma probably is not all that significant if you look at it from just a purely/overall fundamental perspective. But it probably does have some market awareness and psychological significance when you consider that one of the OTC investment themes that has garnered some increased interest recently has been with OTC stocks that have some connections to Nasdaq stocks. The HLTT/Varian/SPK connection is one that very few investors are probably aware of at the moment.
VBIXD(.51)...Gix Media expects $80-90M 2022 revenue......
Added some more shares to my position both before and after the 1:28 reverse split. Risk/reward looks somewhat interesting down around this 50-80 cent price area. The incoming reverse merger target (Gix Media) did a little over $43M revenue in the first 6 months of this year, and the June 2022 (page 19) presentation below has the company providing guidance/expectation of $80-90M revenue for fiscal 2022.
I'm still not completely sure what the final post-RM share structure will look like. There are a few complicating factors (like whether some high-priced warrants get exercised, exactly how a loan to Gix's parent company will be repaid, etc.). But if my rough calculations/guess is reasonably close, I think the shares outstanding will probably be somewhere in the 12.5M to 18M range (my guess is that it will be roughly 15M).
https://mayafiles.tase.co.il/rpdf/1457001-1458000/P1457040-00.pdf
LFEV(.413)...design/manufacture of AREB's e-bikes......
Still holding a position in the LFEV shell, waiting for the reverse merger with Life Electric to be officially completed, and still crossing my fingers there will be some type of momentum run. Share structure and valuation post-RM probably will be unattractive (around 457M outstanding), but the tradeable shares might still be reasonably low.
There has not been any official disclosure yet but it appears that one of the several additional acquisitions that LFEV has been working on is Sierra E-Bikes......
CXKJ's forward split......
I was somewhat disappointed to see CXKJ do a forward split. That pretty much ends the chances of CXKJ uplisting to the Nasdaq anytime soon. I thought with the type of share structure CXKJ had the company was positioning itself reasonably well for an eventual uplisting. I was kind of really looking forward to that, especially when you see just how explosive some of these uplistings/IPOs have been recently (particularly with China-based companies).
I think a couple of months or so ago I remember seeing on the corporate website some references to the possibility of filing an OTCQB application. Based on the language in the parts of the 8-K dealing with the addition of the two new directors, I would assume the company is in fact going to file that application. Since the company already is a current SEC-filer, I would guess this is being done just for the increased market awareness that OTC Markets services might offer. Personally, I think that would probably be a waste of CXKJ's time/resources.
I am a little bit puzzled about why the company did not maintain the 1:5 ratio on its outstanding/authorized structure after the forward split (increase it to 2 billion authorized)......
current outstanding/authorized structure: 40M/200M
new structure: 400M/1B
By only raising the authorized to one billion shares, the net effect of this share structure change is that CXKJ has reduced it authorized shares by 50%. Which would seem to make it more difficult to actually make acquisitions (unless they plan to use their preferred shares for such purposes).
QMEI's purchase of Besra shares......
QMEI...acquired 9.72% of Besra Gold......
I picked up some more shares of QMEI today at around 74-75 cents. Although QMEI has not made any US-filings or social media disclosures yet regarding this acquisition, it appears QMEI has acquired 9.72% of Besra Gold. This company trades on the Australian stock exchange and is primarily focused on gold mining in Malaysia. Besra's exploration targets look like they have (or potentially have) significant deposits of gold.
QMEI acquired these shares from another company, at a more than 450% premium to what Besra was trading at around the time of the acquisition. Date of the acquisition was August 11. According to the filing disclosures in Australia, QMEI paid $5M in cash for this position. Quantum Metal Recovery is a subsidiary that QMEI registered last year.
Besra issued a press release this morning.......
CXKJ...officially starting merger/acquisition phase of its growth.......
I've locked in some profits around the $1.50-2.50 area on CXKJ, but still hold a decent position in anticipation of a possible nice push over $2 again. When CXKJ first went public it mentioned that M&A activity would be a major part of its growth plans. I think they were planning to do at least a couple/few acquisitions per year. According to the corporate website, CXKJ has officially started talks/negotiations with other companies here in the month of August......
Traderfan...QMEI, Esther Law, Asian RMs......
QMEI(.37)...another reference to company desire for Nasdaq listing......
Earlier this year the QMEI CEO mentioned a number of times during interviews/presentations that QMEI will seek a Nasdaq listing at some point. Last week it looks like the company appointed a presumably full-time CFO, replacing Esther Law (one of the co-founders who has her hands full running quite a few businesses in Asia).
About 3 weeks ago this press release from an Asian business awards association once again reiterates QMEI's desire for a Nasdaq listing.......
Traderfan...ADMG legacy valuation is hard to ignore.......
ADMG/EVCI...added to positions......
ADMG: Finished building my position in the ADMG shell with a 90+K block of shares at 6 cents last week. The quarterly filing disclosed that Asia-focused consultant NYJJ (Hong Kong) Limited is paying some of the shell's expenses. That could increase the chances of seeing an Asia-based reverse merger on this shell.
However, when Larry Eastland (family/associates) sold control of the TGRP shell to Szu-Wu Yu (a financial consultant/accountant primarily focused on Asia/Australia) last year, I was 100% convinced that the TGRP shell would see an Asian reverse merger. The TGRP RM went in a totally different geographic direction than I was expecting.
EVCI: I picked up a few more shares of the EVCI shell at 32 cents last week. Ben Berry's last tweet chain regarding EVCI on July 17 mentioned that he was vetting a potential RM target for the shell. It is very possible that EVCI might drop a bit lower in price if I practiced a little more patience here, but I wanted to have some more shares just in case EVCI is getting close to an announcement.......
$EVCI OTCM denied the QB application based on grounds that the company is a shell and if they make it QB they are concerned that there will be an operating business come March (18 Months from September Amended Rule 15c2-11). They also didn't like the preferred control...
— Synergy Management (@synergymgtgroup) July 17, 2022
ADMG(.10)...added to position......
16.1M shares outstanding
4.24M float
Larry Eastland purchased control of this shell around the end of March 2022 (11,866,563 shares).
Since my last post over on the ADMG board, I have been adding to my position at prices under 13 cents. Picked up a 50K block at ten cents today. My current cost basis is now under 12.9 cents.
Over on the ADMG board I mentioned that Eastland had registered a biotech advisory service company in Florida during 2021. I speculated that maybe he might use the ADMG shell for some type of biotech RM. Kind of interesting to note that after I made that post the quarterly filing for TGRP (another company/shell that Eastland was connected with during 2021 before selling it to another party in Asia/Australia ) disclosed that it had been purchased by James Talton. It seems highly likely to me that Eastland had a role in James Talton buying control of that shell. I don't think it is just merely a coincidence that Talton owns a biotech business located in the same city where Eastland established his biotech advisory company.
Perhaps worth noting: TGRP's legacy share valuation at its current bid price is over $11M, and at its current ask price TGRP's legacy valuation is over $21M. Also perhaps worth noting: In the TGRP situation all of the Eastland associated shares were ultimately sold to the new control person. If a similar scenario (structure/price) occurred with this ADMG shell, that would be the equivalent of ADMG trading at a price over $2.5 per share.
James Talton's LinkedIn profile......
https://www.linkedin.com/in/james-talton-a091591/
LUDG/STSN...accumulated positions......
Perhaps against my better judgement, I have accumulated positions in LUDG and STSN. Both are unattractive from a valuation/structure/debt perspective. Plenty of things not to like about both of these stocks.
Having said the above, I am thinking there is a chance that at least one of these stocks will get pushed hard at some point. Both of these companies have changed their business direction relatively recently and for the most part those changes have not received much investor attention yet. Should be potential catalysts coming for both of them. So I have accumulated positions with my fingers crossed and nose plugged.
At least part of LUDG's new business direction apparently will involve an mRNA-based cancer diagnostic test. STSN will be involved with canned oxygen.
Currently averaged in at: LUDG (.032) and STSN (.0147)
CSUI...November 2021 presentation is interesting......
Accumulated a position in CSUI. I think there is a decent chance that the bitcoin mining operations will be among the assets included in this reverse merger. Depending on exactly how they structure this RM, I like the chances of seeing a move into the 15-30+ cent range. That would be a roughly $5-10M valuation on the legacy shares (shares not owned by the incoming RM target/insiders), which should be around 28-29M shares.
Probably would be prudent to wait and see how this RM gets structured, but the valuation/potential looks reasonably good to me so I'm willing to take that chance. CSIU has an early APLD kind of feel about it (before APLD's reverse split and NASDAQ uplisting, its legacy share count was around 9-10M and it reached a legacy valuation over $50M during a time when the OTC Market was more favorable). If CSUI's reverse merger gets structured reasonably well, these sub-10 cent prices might turn out to be nicely profitable.
I don't know what the current status of their mining operations looks like, but the November 2021 presentation is quite interesting. Obviously there is some deep-pocketed people/entities involved with the mining operations. The text and bullet points from slide 9 of that presentation......
edesheim...increased my YBGJ position......
QGSI...Misir's share purchase, MetaTrading Investments......
Picked up some more shares of QGSI at 9 cents and below for a possible short-term trade. I think these last two press releases would seem to bode well for some tradeable opportunities. That looks like a pretty nice personal/financial commitment that Govin Misir has made here: purchase of 90M shares at 20 cents, and apparently a more visible/tangible relationship with his own software company.
I'm not sure if these last two press releases are an indication they are proceeding with development of the MetaTrading Investments subsidiary they formed earlier this year, or if there are other things currently under development. But I would certainly think these PRs are a good sign we will probably be seeing some potentially interesting corporate developments.
The 25-page investment deck for the MetaTrading subsidiary.......
https://www.canva.com/design/DAE5pYK33w4/zVEIzAbeHBwopfuPosKlXA/view/
MedHab, Cypress Technologies...extremely interesting RM......
Settlement agreement was interesting......
CNGI(.60)...added to my position......
CNGI(.60)...added to my position......
ADMG(.10)...added to position.....
TCRI(.62)...regarding position status......
To the person who inquired about my current position status and thoughts on TCRI......
I'm still holding a large position in the TCRI shell. Currently have a little over 746K shares at a cost basis a little over .094 per share. Unless something dramatically negative occurs, I don't have a great deal of interest in selling my position at this kind of price/valuation.
Over the next 4-5 weeks or so we should be seeing TCRI make two periodic filings (the 2021 10-K and 2022 Q1). Between the "subsequent events" section of the annual report and the entirety of the Q1 report, I would think at a minimum we should get some clarity on Munaf Ali's current ownership status with the shell.
I have no idea whether there has been in any significant change in the overall shell situation since the disclosure of the AlphaBit/Munaf purchase of the shell and Munaf Ali's November 2021 mention of what Phoenix intended to use the shell for. If the original purchase agreement was unwound , or if Munaf does still own the shell and has changed his original plans for the shell, I would not automatically/necessarily consider either of those scenarios to be something terribly negative. I am mostly just waiting to see what develops with the shell and will react accordingly.
Obviously there has been a tremendous amount of business activity going on with Phoenix and people surrounding that company since Munaf acquired the TCRI shell, and especially so in calendar 2022. If Munaf/Phoenix are still involved with TCRI, one somewhat interesting thing I have noticed recently is that Reza Dari (who registered AlphaBit LLC in Nevada) has registered another company here in the United States. About 3 weeks ago he registered Ourglass LLC in the state of Texas......
https://opencorporates.com/officers?q=Reza+Dari
Between overall market struggles/volatility and the new inherent danger of investing in fully-reporting SEC OTC Market stocks (thanks to the SEC's September 2021 rules), it is not surprising to see OTC stocks struggling at times. Especially around periodic filing deadlines.
ADMG(.13)...increased position......
ASNBD($1.40)...accumulated a position.....
Outstanding: 5.7M
Float: 570K
Risk/reward on ASNBD in the $1-1.50 price range looks somewhat interesting to me. I started accumulating a position just prior to the reverse split and continued accumulating following the split. Currently averaged in at slightly over $1.30 per share. The valuation I am paying does concern me, but I'm crossing my fingers quite a bit and taking a chance.
I am only aware of (or familiar with) two other reverse mergers that PacificWave has been involved with (MMND, and the most recent one from about 4 years ago -- RKFL). Following PacificWave's purchase of 75-90+% positions, both of those shells had share structures fairly similar to what post-reverse split ASNBD looks like now. It looks like both of those shells/RMs saw bid prices over $5 at some point.
Just based on a very quick, non-detailed look at those shells it looks like PacificWave was able to complete RM agreements that kept the immediate post-RM share structures relatively low (around 25-35M shares outstanding). In a lot of RM scenarios those share structures could have easily ballooned up to 150+M.
So perhaps that bodes well for this shell.
edesheim...YBGJ current thoughts......
I still own my full position of YBGJ (cost basis a little under 54 cents). Most of my recent attention and money has been focused on trying to establish entries or additional accumulation of other situations/shells. Otherwise that 15 cent ask on YBGJ yesterday would have been extremely tempting to me. I came very close to trying to pick up 10K at that price, but got distracted by other things.
I noticed that YBGJ's unrestricted share count increased by 102K on Friday, so maybe that had some connection to the volume that day.
So far I've handled this stock about as poorly as possible (not securing a nice profit near the top, and not taking the tax loss and buying back in at a lower price), so maybe I will end up regretting not aggressively buying around this 10-25 cent price area. When I was considering taking the tax loss in December, I kept looking at the share structure and valuation and just could not gather the will power to press the sell button.
One thing that has me very puzzled is a company that Yulin Cao (a YBGJ director and basically the scientific brains behind the technology) formed in late August 2021. The company is Beijing Bihe Biotechnology and it has products that are generally/somewhat similar to what YBGJ has. I don't recall what the exact verbiage was, but when the website for that company first started to come online it was noted that YBGJ had some sort of connection with it. But as the website continued to evolve/update, that reference was removed. I'm not sure what is going on there, very confusing/puzzling to me......
http://www.iubiotechnology.com/
Hopefully calendar 2022 will finally have the company/stock make some noticeable progress. The most recent S-1/A filing (February 2022) continues to have the 50 cent fixed price for the proposed insider sales and company financing, so that seems encouraging to me. Also from that same filing, the company continues to believe its employee workforce will triple in 2022.
I think YBGJ posts frequently on its Weixin social media account. It is not always company specific information, but occasionally there can be some interesting things related to the company/products. I don't have a Weixin account, but sometimes the company does put its Weixin posts on its website.
You can find it by using this link below, and click on the item at the bottom of the page.......
https://mp.weixin.qq.com/s/2h7bquRRUWnZcYlwQ8EDRg
If for some reason the above link doesn't function, you can go to the link below, and click on the blue and green image with the red "viv cell" lettering.......
http://www.yubogroup.com/details/info.html
One somewhat interesting item I recall seeing from these Weixin posts around mid-October 2021 was a reference to "Phoenix Club". The link I saved for that post no longer functions. For some reason these Weixin-related links do not always maintain functionality, so if there is some important information in the posts you want to reference later you either have to screenshot it or print it off. Unfortunately I did not save any of the text from that post.
There has not been any mention of "Phoenix Club" in any of YBGJ's filings, nor any mention of it since that Weixin post (I don't monitor YBGJ's website on a daily basis, so it is possible I missed something). As best as I can remember from the post, it appeared as though it is some type of regional centers. Whatever it is, YBGJ seemed to be actively developing it (lining up management/investment) and believed it would be an important part of 2022 for the company.
Everything considered I will probably hang on to my shares, might possibly add to my position, and see how things develop here in 2022. Could end up being another bad decision on my part but at a current valuation of around $25M, I think the potential for some decent upside exists.
JRSS(.18)...accumulated a position......
Accumulated some shares of JRSS over the last week around the 14-20 cent range. Currently averaged in at a little over .182 per share. Risk/reward around this price area looks reasonably good to me. Although the OTC market is in an overall very different place/environment compared to the last time JRSS had a large price move (early 2021), it would not surprise me at all if JRSS had another fairly large move sometime during 2022.
The stock still seems to be relatively tightly-held, and the catalyst of the third hospital branch opening should occur here in calendar 2022. Once that branch is open and fully functional it will increase the hospital bed count by over 30%. At the time the company announced the formation/registration of the new branch, they projected it would increase the company revenue by about $8M. My hunch is that number is going to turn out to be somewhat conservative (I'm thinking it might end up being closer to the $10-12M range).
Seems entirely possible to me that JRSS could produce yearly revenue of $50M once that third branch is in full swing. So buying JRSS at a market cap under $4M looks like a pretty interesting risk/reward situation.
GRCYW...accumulated a position......
PIHG...business plan from LinkedIn account......
Based on the business plan description on the recently-created PIHG LinkedIn account, it appears the company will provide financings/investments for other businesses. Since the business plan seems to be somewhat similar to what the previous owner had, and a PIHG-related website was recently registered and brought online, I would assume that new President Simon Littlewood probably plans on keeping the current name.
FINRA seems to be turning what should be just very simple name/symbol changes into a lengthy process/ordeal for companies. So keeping the name the same is just one less headache that new management would have to deal with.
STJO...position status......
I'm still holding my full position as the March 15 soft deadline for the definitive merger agreement approaches. A little over 660K shares with a cost basis under .072 per share.
High risk, but I am hoping to get a minimum of 40-75 cents on that position. That would be a valuation of roughly $5-10M on STJO's 13.4M legacy shares.
If the post-RM structure is reasonably good, I think STJO might have a decent chance at seeing some sustained trading around those kinds of prices/valuations.
AMRR...website has been updating recently......
I picked up some shares at $2.20 today for the move back toward $3 or higher. Over the last week or two the corporate website has been fleshed out a little more (services offered, client list, etc.), so I am anticipating the stock should be getting closer to additional catalysts......
https://multibandglobal.com/
HLTT(.30)...Varian Biopharma going public via SPK SPAC......
Q1 2022...another good quarter......
TCRI...legacy valuation area has produced previous winners......
As I have mentioned in previous posts on this message board and others, I like to use legacy shares and legacy share valuations in my analysis of shells and reverse mergers. For a number/variety of reasons, I have found the use of legacy share/valuation to be extremely helpful in the world of shell/RM investing.
At the risk of having egg on my face if TCRI doesn't turn out the way I expect, it might be worth noting that TCRI has been churning/basing around a legacy share valuation area that has produced some previous, very nice shell/RMs in the last year or so. It certainly doesn't happen in all instances, but sometimes in the life cycle of big shell/RM winners they will churn for awhile somewhere in that $7-15M range (usually it seems to be right around $10M, give or take a couple million dollars). That is basically where TCRI has been churning for awhile now.
I picked out 3 crypto reverse mergers (APLD, MTRT, BOPO) and one non-crypto play (ENGA) that I think most shell investors are familiar with. It should be noted that both MTRT and BOPO have managed to have their recent big moves in what has been a difficult time in the market (inflation, geopolitical conflict, etc). Below I will put their legacy share number and what their legacy share valuation reached after the churning ended. These numbers are mostly from my memory, so they might be slightly off......
APLD -- 9.5M shares, over $50M
MTRT -- 7.5M shares, over $70M
BOPO -- 45M shares, over $40M
ENGA -- 24M shares, over $115M
One other thing that all of those shells shared in common is a retail shareholder base that was a little frustrated/unhappy with the churning period. Nobody (myself included) enjoys sitting through a period where the stock bases, but if TCRI follows the pattern of some of these other extremely profitable shell/RM investments, the gains from this level could be somewhat interesting. This is contingent on TCRI's legacy share count being 10M, of course (see the above post).
BitZERO expected to IPO this year......
Phoenix/Cypher conference appearances on February 22, March 9.......
Both Bijan Alizadeh and Vineet Budki (Cypher Capital CEO) are listed among the speakers at the upcoming Global Blockchain Congress on February 22. Vineet will also be a panelist at the Global Tech Innovation Summit on March 9.
I have included links to a couple videos of Vineet Budki representing Phoenix/Cypher in previous conference settings. Much like Munaf Ali, Vineet seems to be reasonably comfortable with public speaking.......
QMEI...strategic business partnership on February 12.......
QMEI and the Malaysian Islamic Chamber of Commerce entered into a strategic business partnership/cooperation on February 12. Esther Law and the CEO attended the signing ceremony. This agreement should improve/strengthen the growth prospects in Malaysia and also help with the expansion into other countries.
From the statement issued by the President of the Chamber of Commerce.......
QMEI(.929)...accumulated a position......
Accumulated some shares of QMEI over the last 5 trading days, roughly in the 70-91 cent range. Currently averaged in a little under .895 per share. Risk/reward looks somewhat interesting to me under this $1 price level. Should be seeing a couple of quarterly reports (Q1 and Q2) filed over the next couple/few months. I think the explosive potential that QMEI exhibited a couple of months ago still exists here, so I want to have a position built ahead of the next move/spike higher.
Khong Soon Lim (QMEI CEO) briefly appeared in a couple of videos on January 21/27, and some of the comments/statements he made are the reason why I have taken a position here. Let me preface my comments below with an acknowledgement that I may have misheard or misinterpreted his statements. The combination of poor internet connections and heavy accents in these videos make it somewhat excruciating to watch and difficult to completely understand these videos. And using the closed caption feature on the videos can only help so much.
Having said that, these are the things that caught my attention......
1) It is very obvious that QMEI plans to uplist this stock to the Nasdaq at some point. This was repeated a number of times, and not only by the CEO. I believe the CEO is well aware of when QMEI would first become eligible for an uplisting (which would be around one year after the RM, unless they choose to do an accelerated uplisting). When he was talking about the timing of the Nasdaq uplisting he used the words "six months", which would be right around that one-year post-RM time frame.
The CEO said he expects QMEI to see a share price around $6-8 this year. Over the next 3-5 years he expects the share price to reach $100.
2) QMEI is planning to acquire a gold refinery.
3) He mentioned something about a "shop merchant" program or business that will begin next month. I'm thinking this might be some type of digital payment system/app that retail shoppers can use, but I'm not entirely sure what he was referencing there.
4) In both of these videos, the CEO mentions that February 22 will be an important date. He called it a "big event" or "big announcement". Again, I am not sure what he might be referencing, but there is a possibility that this might be in connection to QMEI expanding its platform to more countries. He mentioned something about wanting/expecting 40 countries this year and 60 countries in 3 years.
Here is the link to the videos. They are the videos that have the word "opportunity" in their titles.......
https://www.youtube.com/channel/UC9b3WWAha9CiqhLftCAavLw
Also, it might be worth monitoring Esther Law's Facebook page (she is the co-founder and CFO of QMEI). Once in awhile you might run across an interesting tidbit of information or some behind-the-scenes stuff related to QMEI by following Esther. I have been following her account long before I became interested in QMEI, since she has some loose connection to another China quasi-shell I own. Esther is a very hard-working, impressive lady......
https://www.facebook.com/lawleepoh
Bijan Alizadeh has been interviewed by Irina Heaver......
Irina Heaver is a well-known, well-respected attorney/advisor/investor in the crypto industry, specializing in the geographic regions of the Middle East and Europe. Last Friday (February 4) she tweeted that she has done a video interview with Bijan.
She did not mention when the interview will be released, but from what I understand the interviews she has been doing recently are part of a series of interviews that are being filmed in advance of the upcoming March crypto summit in Dubai. Irina is among those who are expected to be speakers at that summit.
Based on the tweet, the subjects of the Bijan interview were Phoenix's mining facility in the UAE and the venture capital side of the business......
💕🚀🚀🚀🚀💪
— Irina ₿. Heaver (@IrinaHeaver) February 4, 2022
Bijan Alizadeh Fard...Jax.Network advisory board......
During the week of December 20, Bijan Alizadeh Fard (Phoenix Technology Chief Operating Officer and Co-Founder) was appointed to the Jax.Network advisory board. Most likely the people from Jax met with Bijan/Phoenix during the World Digital Mining Summit in early November. Following the Summit, Jax posted a picture taken outside of the Phoenix booth.
Announcement from the Jax December 24 weekly update......
This week, another brilliant person joined our advisory team and therefore you can expect lots of interesting collaborations in the future. We also continued to wrap up our DeFi products. https://t.co/a01j8Ox1im
— Jax.Network (@CommunityJax) December 24, 2021
Excellent Q4...revenue growth accelerating......
Based on the Q4 2021 numbers and the general "vibe" I get from reading accounts of the marketing/financial conferences and meetings, it does appear that business momentum is accelerating. All of this is being accomplished with the company basically having one arm tied behind its back because of the pandemic. The company has had to place most of its focus on its e-commerce platform, rather than the implementation of its smart kiosk growth plans.
The Q1 2022 report is due to be filed in about a month. Should be interesting to see if those fourth quarter numbers are an indication of good things to come.
A comparison of Q3 2021 and Q4 2021 revenue and deferred revenue for CXKJ. It might be worth noting that during the fourth quarter CXKJ showed a profit from operations of $497K........
Q3: Revenue -- $452K Deferred revenue -- $1.78M
Q4: Revenue -- $2.96M Deferred revenue -- $3.12M